- Home
- ADVM vs EPIX Comparison
ADVM vs EPIX Comparison
Compare ADVM & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- EPIX
- Stock Information
- Founded
- ADVM 2006
- EPIX 2009
- Country
- ADVM United States
- EPIX Canada
- Employees
- ADVM N/A
- EPIX N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- ADVM Health Care
- EPIX Health Care
- Exchange
- ADVM Nasdaq
- EPIX Nasdaq
- Market Cap
- ADVM 59.5M
- EPIX 71.5M
- IPO Year
- ADVM 2014
- EPIX N/A
- Fundamental
- Price
- ADVM $2.41
- EPIX $1.70
- Analyst Decision
- ADVM Strong Buy
- EPIX Hold
- Analyst Count
- ADVM 5
- EPIX 3
- Target Price
- ADVM $26.40
- EPIX $2.00
- AVG Volume (30 Days)
- ADVM 430.7K
- EPIX 138.8K
- Earning Date
- ADVM 05-14-2025
- EPIX 05-08-2025
- Dividend Yield
- ADVM N/A
- EPIX N/A
- EPS Growth
- ADVM N/A
- EPIX N/A
- EPS
- ADVM N/A
- EPIX N/A
- Revenue
- ADVM $1,000,000.00
- EPIX N/A
- Revenue This Year
- ADVM N/A
- EPIX N/A
- Revenue Next Year
- ADVM $42.58
- EPIX N/A
- P/E Ratio
- ADVM N/A
- EPIX N/A
- Revenue Growth
- ADVM N/A
- EPIX N/A
- 52 Week Low
- ADVM $1.78
- EPIX $1.40
- 52 Week High
- ADVM $10.14
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- ADVM 40.10
- EPIX 51.94
- Support Level
- ADVM $2.15
- EPIX $1.60
- Resistance Level
- ADVM $2.33
- EPIX $1.70
- Average True Range (ATR)
- ADVM 0.23
- EPIX 0.04
- MACD
- ADVM 0.04
- EPIX -0.00
- Stochastic Oscillator
- ADVM 52.58
- EPIX 82.83
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.